bezafibrate (Bezalip) Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bezafibrate is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL.   Wikipedia

Chemistry

  • SMILES: CC(C)(Oc1ccc(CCNC(=O)c2ccc(Cl)cc2)cc1)C(=O)O
  • InChIKey: IIBYAHWJQTYFKB-UHFFFAOYSA-N
  • Mol. Mass: 361.83
  • ALogP: 3.55
  • ChEMBL Molecule:
    bezafibrate  
More Chemistry

Pharmacology

Alternative names

2-(p-(2-(p-chlorobenzamido)ethyl)phenoxy)-2-methylpropionic acid | befizal | benzofibrate | bezafibrat | bezafibrate | bezafibrato | bezafibratum | bezagen xl | bezalip | bezalip-mono | bezatol | bezatol sr (tn) | bm 15.075 | cedur | difaterol | fibrazate xl | liparol xl | zimbacol xl

Organizations (33)

Research & Development (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (17)

Approved Indications (1)


 

Hyperlipidemias

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Acute Coronary Syndrome (Phase 4)

Bipolar Disorder (Phase 2)

Carnitine O-Palmitoyltransferase (Phase 3)

Cholangitis (Phase 3)

Cholangitis, Sclerosing (Phase 3)

Cholestasis (Phase 3)

Deficiency Diseases (Phase 2)

Depression (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyslipidemias (Phase 2)

Hypercholesterolemia (Phase 4)

Liver Cirrhosis, Biliary (Phase 3)

Mitochondrial Diseases (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myocardial Infarction (Phase 4)

Self Efficacy (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial Organizations: 33

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue